Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 12/2015

01.12.2015 | Original Article – Clinical Oncology

Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma

verfasst von: Myungsun Shim, Cheryn Song, Sejun Park, Seung-Kwon Choi, Yong Mee Cho, Choung-Soo Kim, Hanjong Ahn

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated the expression status of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-B and their receptors in organ-confined clear cell renal cell carcinoma (ccRCC) to evaluate their prognostic significance after radical surgery.

Methods

In 758 consecutive patients diagnosed with pT1-2N0 ccRCC between 2007 and 2012, we prospectively investigated the expression levels of VEGF, PDGF-B, VEGF receptor (VEGFR) and PDGF receptor (PDGFR)-β via immunohistochemistry. Clinicopathologic parameters and expression of the angiogenic factors were analyzed with respect to recurrence-free survival (RFS) after nephrectomy. The median follow-up was 29.5 months (IQR 21.5, 39.6) after surgery.

Results

Partial nephrectomy had been performed in 48.5 % of the patients, and tumors were staged as pT1a in 514 (67.8 %), pT1b in 192 (25.3 %) and pT2 in 52 (6.9 %). VEGF, PDGF and their receptors were identified in the cytoplasm and membranes of the tumor cells. Expression level of VEGFR inversely correlated with both tumor size (r = −0.076, p = 0.014) and nuclear grade (r = −0.297, p = 0.004). As for PDGF-B, the expression level showed an inverse correlation with tumor size (r = −0.216, p < 0.001) while PDGFR-β inversely correlated with nuclear grade (r = −0.341, p = 0.001). On multivariate analysis, age, pathologic stage, nuclear grade and PDGFR-β expression (high vs. low or none, HR 3.121 95 % CI 1.300–7.493, p = 0.011) were independently prognostic of RFS after nephrectomy.

Conclusions

In organ-confined ccRCC, high expression of PDGFR-β was independently predictive of poorer RFS after nephrectomy.
Literatur
Zurück zum Zitat Amin MB, Amin MB, Tamboli P et al (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 26(3):281–291CrossRefPubMed Amin MB, Amin MB, Tamboli P et al (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 26(3):281–291CrossRefPubMed
Zurück zum Zitat Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410CrossRefPubMed Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410CrossRefPubMed
Zurück zum Zitat Cao Y (2013) Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol Med 19(8):460–473CrossRefPubMed Cao Y (2013) Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol Med 19(8):460–473CrossRefPubMed
Zurück zum Zitat Darwish OM, Kapur P, Youssef RF et al (2013) Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology 81(3):581–586CrossRefPubMed Darwish OM, Kapur P, Youssef RF et al (2013) Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology 81(3):581–586CrossRefPubMed
Zurück zum Zitat Delahunt B, Kittelson JM, McCredie MR, Reeve AE, Stewart JH, Bilous AM (2002) Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 94(3):658–664CrossRefPubMed Delahunt B, Kittelson JM, McCredie MR, Reeve AE, Stewart JH, Bilous AM (2002) Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 94(3):658–664CrossRefPubMed
Zurück zum Zitat Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663CrossRefPubMed Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663CrossRefPubMed
Zurück zum Zitat Gerber HP, Hillan KJ, Ryan AM et al (1999) VEGF is required for growth and survival in neonatal mice. Development 126(6):1149–1159PubMed Gerber HP, Hillan KJ, Ryan AM et al (1999) VEGF is required for growth and survival in neonatal mice. Development 126(6):1149–1159PubMed
Zurück zum Zitat Gilbert SM, Whitson JM, Mansukhani M et al (2006) Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology 67(5):942–945CrossRefPubMed Gilbert SM, Whitson JM, Mansukhani M et al (2006) Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology 67(5):942–945CrossRefPubMed
Zurück zum Zitat Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283–1316PubMed Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283–1316PubMed
Zurück zum Zitat Karakiewicz PI, Jeldres C, Suardi N et al (2008) Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J 2(6):610–617PubMedCentralPubMed Karakiewicz PI, Jeldres C, Suardi N et al (2008) Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J 2(6):610–617PubMedCentralPubMed
Zurück zum Zitat Kim WY, Kaelin WG (2006) Molecular pathways in renal cell carcinoma–rationale for targeted treatment. Semin Oncol 33(5):588–595CrossRefPubMed Kim WY, Kaelin WG (2006) Molecular pathways in renal cell carcinoma–rationale for targeted treatment. Semin Oncol 33(5):588–595CrossRefPubMed
Zurück zum Zitat Kim HL, Seligson D, Liu X et al (2004) Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10(16):5464–5471CrossRefPubMed Kim HL, Seligson D, Liu X et al (2004) Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10(16):5464–5471CrossRefPubMed
Zurück zum Zitat Komai Y, Fujii Y, Iimura Y et al (2011) Young age as favorable prognostic factor for cancer-specific survival in localized renal cell carcinoma. Urology 77(4):842–847CrossRefPubMed Komai Y, Fujii Y, Iimura Y et al (2011) Young age as favorable prognostic factor for cancer-specific survival in localized renal cell carcinoma. Urology 77(4):842–847CrossRefPubMed
Zurück zum Zitat Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B (2005) The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11(3):1129–1135PubMed Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B (2005) The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11(3):1129–1135PubMed
Zurück zum Zitat Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89(3):604–614CrossRefPubMed Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89(3):604–614CrossRefPubMed
Zurück zum Zitat Nicol D, Hii SI, Walsh M et al (1997) Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 157(4):1482–1486CrossRefPubMed Nicol D, Hii SI, Walsh M et al (1997) Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 157(4):1482–1486CrossRefPubMed
Zurück zum Zitat Ostman A, Heldin CH (2007) PDGF receptors as targets in tumor treatment. Adv Cancer Res 97:247–274CrossRefPubMed Ostman A, Heldin CH (2007) PDGF receptors as targets in tumor treatment. Adv Cancer Res 97:247–274CrossRefPubMed
Zurück zum Zitat Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166(5):1611–1623CrossRefPubMed Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166(5):1611–1623CrossRefPubMed
Zurück zum Zitat Park BK, Kim CK, Park SY, Shen SH (2013) Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease: indications, techniques, complications, and outcomes. Acta Radiol 54(4):418–427CrossRefPubMed Park BK, Kim CK, Park SY, Shen SH (2013) Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease: indications, techniques, complications, and outcomes. Acta Radiol 54(4):418–427CrossRefPubMed
Zurück zum Zitat Rajandram R, Yap NY, Pailoor J et al (2014) Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal: potential biomarker significance. Pathology 46(6):518–522. doi:10.1097/PAT.0000000000000145 CrossRefPubMed Rajandram R, Yap NY, Pailoor J et al (2014) Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal: potential biomarker significance. Pathology 46(6):518–522. doi:10.​1097/​PAT.​0000000000000145​ CrossRefPubMed
Zurück zum Zitat Rioux-Leclercq N, Fergelot P, Zerrouki S et al (2007) Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 38(10):1489–1495CrossRefPubMed Rioux-Leclercq N, Fergelot P, Zerrouki S et al (2007) Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 38(10):1489–1495CrossRefPubMed
Zurück zum Zitat Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG (2009) Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol 181(2):506–511PubMedCentralCrossRefPubMed Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG (2009) Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol 181(2):506–511PubMedCentralCrossRefPubMed
Zurück zum Zitat Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A (2003) Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120(1):107–112CrossRefPubMed Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A (2003) Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120(1):107–112CrossRefPubMed
Zurück zum Zitat Tawfik OW, Kramer B, Shideler B, Danley M, Kimler BF, Holzbeierlein J (2007) Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. Arch Pathol Lab Med 131(2):261–267PubMed Tawfik OW, Kramer B, Shideler B, Danley M, Kimler BF, Holzbeierlein J (2007) Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. Arch Pathol Lab Med 131(2):261–267PubMed
Zurück zum Zitat Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A (2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163(4):1090–1095 quiz 1295 CrossRefPubMed Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A (2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163(4):1090–1095 quiz 1295 CrossRefPubMed
Metadaten
Titel
Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma
verfasst von
Myungsun Shim
Cheryn Song
Sejun Park
Seung-Kwon Choi
Yong Mee Cho
Choung-Soo Kim
Hanjong Ahn
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-015-2019-x

Weitere Artikel der Ausgabe 12/2015

Journal of Cancer Research and Clinical Oncology 12/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.